Head and neck cancer is the sixth most common cancer, representing about 5% of all cancers. Each year, more than half a million new cases are diagnosed worldwide. [1] [2] [3] Over the past decade, the important role of different growth factors and their receptors and signal transduction pathways in the genesis and progression of tumours has been well recognised, and their mechanism of action and interaction is gradually being unravelled. [4] [5] [6] [7] [8] [9] [10] The ErbB family comprises four members: human epidermal growth factor receptor (EFGR; HER 1), HER2 (c-erb-B2), HER3 (cerb-B3) and HER4 (c-erb-B4).
oropharynx, hypopharynx or larynx to radiotherapy alone or to radiotherapy in combination with weekly cetuximab. There was a significant increase in the median duration of loco-regional control (24.4 versus 14.9 months; p=0.005) and the median duration of survival (49 versus 29.3 months; p=0.03). The only differences in grade 3/4 acute toxicity were acneiform rash and infusion reactions, which occurred in 17 and 3% of patients, respectively. In particular, the grade 3/4 radiationrelated mucosal toxicity was no worse in the cetuximab arm (54 versus 52%). The trial was conceived before the publication of a meta-analysis that clearly established the superiority of cisplatin-based chemoradiation over radiotherapy alone as definitive treatment for loco-regionally advanced SCCHN. Thus, the control arm used in the trial can no longer be considered the current standard of care for this population.
Cetuximab was added to cisplatin and concomitant boost radiotherapy in a pilot phase II study conducted at the Memorial Sloan-Kettering Cancer Center. 31 Twenty-two previously untreated patients with stage III or IV non-metastatic SCCHN were enrolled. The study was closed before it reached planned accrual because of toxicity concerns. Two patients died while still on study (one from pneumonia and one from an unknown cause). After that, three more non-fatal but serious adverse events occurred (one bacteraemia, one atrial fibrillation and one myocardial infarction), prompting study closure. However, three-year overall survival, progression-free survival (PFS) and loco-regional control rates were 76, 5 and 71%, respectively. Despite the early deaths, outcome compared favourably with those reported in the literature for patients with locally advanced SCCHN who were treated with chemoradiation alone.
Moreover, in retrospect the significant adverse events were not clearly attributable to the investigational therapy. Therefore, although this regimen could not be recommended outside a clinical trial, the results were compelling enough to launch a randomised phase III Radiation Therapy Oncology Group (RTOG) study comparing this regimen with standard cisplatin-based chemoradiation. This trial will hopefully help to elucidate the question of how cetuximab fits into the current treatment strategies for loco-regionally advanced SCCHN. Kies et al. 32 added cetuximab to weekly paclitaxel 135mg/m 2 and carboplatin area under the curve (AUC) 2 as induction regimen in treatment-naïve locally advanced SCCHN. After six weekly administrations of the regimen all patients had a response, with 27% of these complete responses. Severe skin toxicity occurred in 47% of the patients. Severe skin reactions were observed by others when cetuximab was added to a taxane-containing triplet (Vermorken, personal communication) .
Cetuximab has been studied extensively in recurrent and metastatic disease, both in first-and second-line treatment (see Table 2 ). In terms of first-line treatment, Burtness et al. 33 randomised 117 patients with recurrent or metastatic SCCHN to cisplatin plus placebo or cisplatin plus cetuximab. No prior chemotherapy for recurrent and/or metastatic disease had been given to these patients. Objective response rate was 26% in the cetuximab arm and 10% in the placebo arm. PFS was longer in the cetuximab arm (4.2 versus 2.7 months). However, this difference was not statistically significant. This was probably due to the longer than expected PFS in the control arm, which resulted in a lower than intended power of the study to detect a statistically significant difference. There was no difference in overall survival between the two arms for the entire study population. However, there was a survival benefit for the subset of patients who developed cetuximab-related skin toxicity. Bourhis et al. 34 added cetuximab to carboplatin AUC 5 or cisplatin 100mg/m 2 on day one followed by a continuous infusion of 5-fluorouracil (5-FU) at escalating doses of 600, 800 and 1,000mg/m 2 /day. Eligible patients had recurrent and/or metastatic SCCHN and had not received prior chemotherapy for this disease setting. Fifty-three patients were included in this phase I/II study.
The dose of 1,000mg/m 2 of 5-FU was judged to be safe and tolerable and was recommended for further studies. The overall response rate was 36%.
Median time to progression in this latter study was 5.1 months and median overall survival was 9.8 months. The benefit of this combined approach (cetuximab plus platinum/5-FU) was studied in a direct comparison with platinum/5-FU alone in a large phase III trial (Erbitux in First-line Treatment of Recurrent or Metastatic Head and Neck Cancer [EXTREME] study). 35 The addition of cetuximab prolongs overall survival (Vermorken, personal communication) . Four hundred and forty-two patients were randomised to receive either chemotherapy alone (cisplatin 100mg/m 2 or carboplatin AUC 5 on day one followed by 5-fluorouracil 1,000mg/m 2 /day for four days) or the same regimen combined with weekly cetuximab. Cycles were repeated every three weeks for a maximum of six cycles. Thereafter, in the combined arm cetuximab was continued as a single agent until disease progression or unacceptable toxicity -whichever came first. No cross-over was permitted in this study. Patients who had received prior chemotherapy were excluded, except when this had been part of their primary treatment, provided this chemotherapy was ended at least six months before inclusion in the study.
The primary end-point was overall survival. The study was designed to detect an increase in median survival from 7.5 to 9.5 months. The addition of cetuximab increased the median overall survival by 2.7 months from 7.4 to 10.1 months (hazard ratio 0.797, p=0.036). With the addition of cetuximab, the response rate increased from 19.5 to 35.6% (p<0.0001) and the median PFS was prolonged by 2.3 months from 3.3 to 5.6 months (p<0.0001). The addition of cetuximab did not modify the characteristic adverse event profile of platinum-based chemotherapy and did not have a negative impact on quality of life.
As for second-line treatment, three phase II trials examined the role of cetuximab in platinum-resistant disease. [36] [37] [38] Baselga et al. 36 added weekly cetuximab to platinum-based chemotherapy in 96 patients with platinum-refractory SCCHN. The objective response rate in this multicentre phase II study was 10% and the median time to progression and overall survival were 85 and 183 days, respectively. Herbst et al. 37 Nimotuzumab (h-R3) 45, 46 is a humanised IgG1 mouse antibody. Preliminary data suggest that therapeutic levels of h-R3 can be achieved without eliciting skin toxicity. This is the most common side effect of the other anti-EGFR directed antibodies. In phase I studies h-R3 was added to radiation weeks and median overall survival was six months. No difference was detected based on HER1/EGFR expression, but patients who developed at least grade 2 skin rash had a significantly better survival (see Table 3 ).
The optimal way of integrating the TKI into the current treatment strategies for head and neck cancer has yet to be determined, taking into consideration the experience with EGFR TKIs in NSCLC, where adding erlotinib or gefitinib to standard chemotherapy did not improve the outcome compared with chemotherapy alone. [57] [58] [59] The radiosensitising and chemosensitising properties of gefitinib are sequence-dependent in several SCCHN lines. [60] [61] [62] Synergy was observed when gefitinib was applied before radiation or before or during cisplatin and 5-FU. However, antagonism occurred when gefitinib application followed chemotherapy. 60 Other investigators detected synergism when gefitinib was applied during or after docetaxel or gemcitabine, but antagonism in some cell lines when gefitinib preceded docetaxel. 61, 62 Induction chemotherapy followed by concomitant chemoradiation is a treatment paradigm that has recently gained much attention. Cohen et al. 63 treated 69 patients with stage III or IV SCCHN with two cycles of induction chemotherapy (carboplatin and paclitaxel) followed by an alternating chemotherapy and radiation regimen and added gefitinib 250mg/day. After chemoradiation, gefitinib was continued for two years.
Thirty-seven of the 42 evaluable patients (88%) had a complete response.
Grade 3/4 toxicities were consistent with prior chemoradiation trials using the same regimen. After a median follow-up of 294 days, two patients had progressive disease and four patients had died. Phase II trials are planned or ongoing. However, as there are data suggesting that when erlotinib is added to weekly docetaxel lowering of the dose of both drugs may be necessary, 67 caution is still warranted when combining chemotherapy and TKIs.
In a so-called 'window of opportunity' study, Delord et al. 68 
Epidermal Growth Factor Receptor Mutations
The search for EGFR mutations is an area of active investigation. An EGFR mutation of particular importance is EGFRvIII. It is a ligand-independent, constitutively phosphorylated form of EGFR with enhanced tumourigenicity and radioresistance in pre-clinical models. [71] [72] [73] EGFRvIII involves deletion of clear. [77] [78] [79] [80] [81] [82] In vitro NSCLC cell lines harbouring EGFR mutations were more sensitive to gefitinib, but their sensitivity to cetuximab was similar to that of EGFR wild-type cell lines. 83 Gefitinib-sensitising EGFR mutations have been described in an oesophageal cancer cell line 84 and in oesophageal tumours. 85 The incidence of EGFR mutations in SCCHN is currently not known and varies from series to series. 86 Human Epidermal Growth Factor 2 HER2 (or ErbB2) is expressed in 40-60% of SCCHN and is also associated with a worse outcome. 93 The ErbB2-directed antibody trastuzumab was added to paclitaxel and carboplatin in a phase II study that included patients with metastatic or recurrent SCCHN. 94 The response rate (36%) was not higher than expected with this chemotherapy regimen alone. Lapatinib is a selective and potent dual competitive reversible inhibitor of the EGFR and ErbB2 TK. 25 As a single agent, lapatinib is well tolerated but appears to have little, if any, activity in either EGFR inhibitor-naïve or -refractory patients with recurrent or metastatic SCCHN. 95 Abidoye et al. 95 did not observe any objective responses in 42 patients and found a median PFS of six weeks. The combination of lapatinib with conventional radiation (70Gy) and cisplatin 100mg/m 2 every three weeks was tested in a phase I dose-escalating study. 96 The optimal dose was determined to be 1,500mg/day. Seventeen of the 22 patients were evaluable and 74% achieved a complete response. The others had a partial response. Toxicities were no different to those typically observed with concurrent cisplatin and radiotherapy.
Combinations of Targeting Agents
Cyclo-oxygenase 2 (COX-2) expression was found to be an independent prognostic predictor of disease-free survival in some series of oral squamous cell carcinoma. 97 profile. The combination of celecoxib and gefitinib was tested in a phase I dose-finding study at the Dana Farber Cancer Institute. 110 All patients had previously been treated with chemotherapy or radiochemotherapy. At doses of 400 and 500mg twice-daily, no dose-limiting toxicities were encountered. The incidence of diarrhoea and rash was similar to the reported incidence of these toxicities in phase II studies of gefitinib 250 or 500mg/day in SCCHN. The response rate was 22%. The median duration of response was 4.8 months; the median progression and overall survival
Targeting the ErbB Family in Head and Neck Cancer were three and six months, respectively. The majority of studies examining the prognostic significance of vascular endothelial growth factor (VEGF) expression observed a worse outcome in patients with SCCHN expressing VEGF and VEGF receptor-2. 111 Mauer et al. 112 combined erlotinib 150mg/day with the humanised VEGF-A directed antibody bevacizumab, which was administered every three weeks in doses increasing from 5 to 15mg/kg. There were no dose-limiting toxicities. After two cycles of treatment, seven of the nine evaluable patients had stable disease and a partial response was documented in one. The dose of bevacizumab could be safely raised to 15mg/m 2 every three weeks. This dose was subsequently taken into a phase II study. Preliminary data on 28 evaluable patients were reported. 113 Five out of 28 patients had a response (two complete responses and three partial responses). Median progression-free survival was 127 days and median overall survival was 226 days. Pre-clinical data 114 suggest synergy when gefitinib and irradiation are combined with AZD2171, a highly potent, orally active, VEGF signalling inhibitor. 
Conclusion

